Penny Stock Watch: Milestone Jumps While XORTX, bioAffinity Tumble Today

Key Highlights

• Four penny stocks in the healthcare and biotech space, all trading under USD 5, saw sharp price swings today.
• Milestone Pharmaceuticals climbed after enrolling its first European patient in a Phase 3 trial for an irregular heartbeat condition.
• XORTX Therapeutics and bioAffinity Technologies both tumbled more than 14% after company-specific news hit investor sentiment hard.
• Basel Medical Group priced a new stock offering to raise roughly USD 7.98 million in gross proceeds for the company.

Penny stocks move fast, and today's crop of small healthcare names proved it. Trading under USD 5 a share, these four companies saw some of the sharpest single-day swings in the sector, driven by everything from trial progress to a fresh stock sale. Here is a simple look at what happened with each one.

Milestone Pharmaceuticals (NASDAQ:MIST): First European Patient Enrolled in Key Heart Trial

Milestone Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing cardiovascular medicines. The company announced that the first patient in Europe has been enrolled in its Phase 3 trial called ReVeRA-301, which is testing a nasal spray treatment for a fast, irregular heartbeat condition linked to atrial fibrillation. The trial is now recruiting across the United States, Canada, and Europe, working toward a target of about 150 patients. Investors responded well to the sign of steady global progress, and Milestone shares jumped 6.28%, trading around USD 0.76.

XORTX Therapeutics (NASDAQ:XRTX): Gout Drug Filing Plan Fails to Lift the Stock

XORTX Therapeutics is a late-stage clinical pharmaceutical company developing therapies for gout and progressive kidney disease. The company shared plans to file a Clinical Trial Application with Health Canada for its gout treatment program, XRx-026. The filing is meant to support a planned study in Canada that could help speed up data collection ahead of a future U.S. drug application. While the update itself was about regulatory progress, XORTX shares fell sharply, down 14.59% to around USD 1.58, suggesting some investors may have expected more concrete trial results rather than a filing plan.

Basel Medical Group (NASDAQ:BMGL): Fresh Stock Offering Priced at USD 1.33 a Unit

Basel Medical Group is a Singapore-based healthcare company providing orthopedic, neurosurgical, and general medical services. The company priced a registered direct stock offering at USD 1.33 per unit, aiming to raise close to USD 7.98 million in gross proceeds before fees. The deal included both shares and warrants, with company insiders and major shareholders agreeing to lock-up terms for 180 days. Shares slipped slightly, down 0.28% and trading around USD 3.59, as the market weighed the capital raise against the dilution it brings for existing shareholders.

bioAffinity Technologies, (NASDAQ:BIAF): Lung Cancer Test Maker Slides on Capital Raise

bioAffinity Technologies is a biotechnology company focused on noninvasive, early-stage lung cancer diagnosis. The company saw one of the steepest drops of the week. Shares fell 15.16% to around USD 4.79, following news of a stock and warrant sale aimed at raising roughly USD 4 million for the company. Capital raises like this can be necessary for small biotech firms to keep funding research, but they often pressure the stock price in the short term as new shares enter the market.

Final Analysis

Penny stocks in healthcare can be some of the most volatile names on the market, and today was a clear example. A single press release, whether it is a trial update, a regulatory filing, or a stock offering, can swing these small-cap names by double digits in a single session. For readers following this corner of the market, it is worth remembering that low share prices often come with low trading volumes and smaller companies, which can make price swings sharper in both directions.